Lucid Diagnostics Inc. — Form 8-K

Lucid Diagnostics announced three regulatory wins: (1) CMS Medicare Advisory Panel recommended maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule (PLA code 0114U, effective CY2021); (2) AMA CPT Editorial Panel approved a new Category III CPT code for non-endoscopic cell collection with EsoCheck; (3) CDC/NCHS ICD-10 Committee favorably received proposed diagnosis code R85.83 for positive EsoGuard results. Lucid began Medicare claims submission in Texas immediately and will do so in California once LCD is finalized. No dollar amounts or share counts disclosed.